{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:44:44Z","timestamp":1792233884448,"version":"4.4.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T00:00:00Z","timestamp":1775347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T00:00:00Z","timestamp":1775347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Vessels"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s00380-026-02680-5","type":"journal-article","created":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T19:43:10Z","timestamp":1775418190000},"page":"749-759","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Natriuretic peptides are integral in reclassifying heart failure stage and risk"],"prefix":"10.1007","volume":"41","author":[{"given":"Nicholas","family":"Wettersten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9053-1099","authenticated-orcid":false,"given":"Yu","family":"Horiuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori B.","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreya","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Asami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,5]]},"reference":[{"issue":"4","key":"2680_CR1","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jacc.2022.11.023","volume":"81","author":"SJ Greene","year":"2023","unstructured":"Greene SJ, Bauersachs J, Brugts JJ, Ezekowitz JA, Lam CSP, Lund LH, Ponikowski P, Voors AA, Zannad F, Zieroth S, Butler J (2023) Worsening heart failure: nomenclature, epidemiology, and future directions: JACC review topic of the week. J Am Coll Cardiol 81(4):413\u2013424. https:\/\/doi.org\/10.1016\/j.jacc.2022.11.023","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"2680_CR2","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW (2022) 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 79(17):1757\u20131780. https:\/\/doi.org\/10.1016\/j.jacc.2021.12.011","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2680_CR3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1001\/jama.2013.7588","volume":"310","author":"M Ledwidge","year":"2013","unstructured":"Ledwidge M, Gallagher J, Conlon C, Tallon E, O\u2019Connell E, Dawkins I, Watson C, O\u2019Hanlon R, Bermingham M, Patle A, Badabhagni MR, Murtagh G, Voon V, Tilson L, Barry M, McDonald L, Maurer B, McDonald K (2013) Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA 310(1):66\u201374. https:\/\/doi.org\/10.1001\/jama.2013.7588","journal-title":"JAMA"},{"issue":"12","key":"2680_CR4","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1001\/jamacardio.2021.3187","volume":"6","author":"JD Berry","year":"2021","unstructured":"Berry JD, Nambi V, Ambrosius WT, Chen H, Killeen AA, Taylor A, Toto RD, Soliman EZ, McEvoy JW, Pandey A, Joshi PH, Blankenberg S, Kitzman DW, Ballantyne CM, de Lemos JA (2021) Associations of high-sensitivity troponin and natriuretic peptide levels with outcomes after intensive blood pressure lowering: findings from the SPRINT randomized clinical trial. JAMA Cardiol 6(12):1397\u20131405. https:\/\/doi.org\/10.1001\/jamacardio.2021.3187","journal-title":"JAMA Cardiol"},{"issue":"24","key":"2680_CR5","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornoe CW, Ryan DH, Investigators ST (2023) Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 389(24):2221\u20132232. https:\/\/doi.org\/10.1056\/NEJMoa2307563","journal-title":"N Engl J Med"},{"issue":"4","key":"2680_CR6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, Investigators D-T (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347\u2013357. https:\/\/doi.org\/10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"issue":"22","key":"2680_CR7","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, Investigators E-RO (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"issue":"4","key":"2680_CR8","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jchf.2022.12.005","volume":"11","author":"X Jia","year":"2023","unstructured":"Jia X, Al Rifai M, Ndumele CE, Virani SS, de Lemos JA, Lee E, Shah AM, Echouffo-Tcheugui JB, Bozkurt B, Hoogeveen R, Selvin E, Ballantyne CM, Nambi V (2023) Reclassification of pre-heart failure stages using cardiac biomarkers: the ARIC study. JACC Heart Fail 11(4):440\u2013450. https:\/\/doi.org\/10.1016\/j.jchf.2022.12.005","journal-title":"JACC Heart Fail"},{"issue":"23","key":"2680_CR9","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.jacc.2023.04.007","volume":"81","author":"R Mohebi","year":"2023","unstructured":"Mohebi R, Wang D, Lau ES, Parekh JK, Allen N, Psaty BM, Benjamin EJ, Levy D, Wang TJ, Shah SJ, Gottdiener JS, Januzzi JL Jr., Ho JE (2023) Effect of 2022 ACC\/AHA\/HFSA criteria on stages of heart failure in a pooled community cohort. J Am Coll Cardiol 81(23):2231\u20132242. https:\/\/doi.org\/10.1016\/j.jacc.2023.04.007","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"2680_CR10","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.jacep.2023.06.008","volume":"9","author":"MR Abu-Qaoud","year":"2023","unstructured":"Abu-Qaoud MR, Kumar A, Tarun T, Abraham S, Ahmad J, Khadke S, Husami R, Kulbak G, Sahoo S, Januzzi JL Jr., Neilan TG, Baron SJ, Martin D, Nohria A, Reynolds MR, Kosiborod M, Dani SS, Ganatra S (2023) Impact of SGLT2 inhibitors on AF recurrence after catheter ablation in patients with type 2 diabetes. JACC Clin Electrophysiol 9(10):2109\u20132118. https:\/\/doi.org\/10.1016\/j.jacep.2023.06.008","journal-title":"JACC Clin Electrophysiol"},{"issue":"1","key":"2680_CR11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jchf.2023.08.026","volume":"12","author":"V Avula","year":"2024","unstructured":"Avula V, Sharma G, Kosiborod MN, Vaduganathan M, Neilan TG, Lopez T, Dent S, Baldassarre L, Scherrer-Crosbie M, Barac A, Liu J, Deswal A, Khadke S, Yang EH, Ky B, Lenihan D, Nohria A, Dani SS, Ganatra S (2024) SGLT2 Inhibitor use and risk of clinical events in patients with cancer therapy-related cardiac dysfunction. JACC Heart Fail 12(1):67\u201378. https:\/\/doi.org\/10.1016\/j.jchf.2023.08.026","journal-title":"JACC Heart Fail"},{"key":"2680_CR12","doi-asserted-by":"publisher","first-page":"132611","DOI":"10.1016\/j.ijcard.2024.132611","volume":"418","author":"Y Horiuchi","year":"2024","unstructured":"Horiuchi Y, Wettersten N, Asami M, Yahagi K, Komiyama K, Yuzawa H, Tanaka J, Aoki J, Tanabe K (2024) Glucagon-like peptide-1 receptor agonists improve outcomes in individuals with type 2 diabetes with and without heart failure. Int J Cardiol 418:132611. https:\/\/doi.org\/10.1016\/j.ijcard.2024.132611","journal-title":"Int J Cardiol"},{"issue":"2","key":"2680_CR13","doi-asserted-by":"publisher","first-page":"ooad035","DOI":"10.1093\/jamiaopen\/ooad035","volume":"6","author":"MB Palchuk","year":"2023","unstructured":"Palchuk MB, London JW, Perez-Rey D, Drebert ZJ, Winer-Jones JP, Thompson CN, Esposito J, Claerhout B (2023) A global federated real-world data and analytics platform for research. JAMIA Open 6(2):ooad035. https:\/\/doi.org\/10.1093\/jamiaopen\/ooad035","journal-title":"JAMIA Open"},{"issue":"8","key":"2680_CR14","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1016\/j.jacep.2024.03.031","volume":"10","author":"DI Satti","year":"2024","unstructured":"Satti DI, Karius A, Chan JSK, Isakadze N, Yadav R, Garg K, Aronis KN, Marine JE, Berger R, Calkins H, Spragg D (2024) Effects of glucagon-like peptide-1 receptor agonists on atrial fibrillation recurrence after catheter ablation. JACC Clin Electrophysiol 10(8):1848\u20131855. https:\/\/doi.org\/10.1016\/j.jacep.2024.03.031","journal-title":"JACC Clin Electrophysiol"},{"issue":"6","key":"2680_CR15","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1016\/j.amjmed.2019.10.030","volume":"133","author":"AM Chamberlain","year":"2020","unstructured":"Chamberlain AM, Boyd CM, Manemann SM, Dunlay SM, Gerber Y, Killian JM, Weston SA, Roger VL (2020) Risk factors for heart failure in the community: differences by age and ejection fraction. Am J Med 133(6):e237\u2013e248. https:\/\/doi.org\/10.1016\/j.amjmed.2019.10.030","journal-title":"Am J Med"},{"issue":"25","key":"2680_CR16","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1016\/j.jacc.2007.09.021","volume":"50","author":"LB Daniels","year":"2007","unstructured":"Daniels LB, Maisel AS (2007) Natriuretic peptides. J Am Coll Cardiol 50(25):2357\u20132368. https:\/\/doi.org\/10.1016\/j.jacc.2007.09.021","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2680_CR17","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.ijcard.2012.11.065","volume":"168","author":"S Khatibzadeh","year":"2013","unstructured":"Khatibzadeh S, Farzadfar F, Oliver J, Ezzati M, Moran A (2013) Worldwide risk factors for heart failure: a systematic review and pooled analysis. Int J Cardiol 168(2):1186\u20131194. https:\/\/doi.org\/10.1016\/j.ijcard.2012.11.065","journal-title":"Int J Cardiol"},{"issue":"6","key":"2680_CR18","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00380-023-02238-9","volume":"38","author":"S Nohara","year":"2023","unstructured":"Nohara S, Ishii K, Shibata T, Obara H, Miyamoto T, Ueno T, Kakuma T, Fukumoto Y (2023) Risk factor structure of heart failure in patients with cancer after treatment with anticancer agents\u2019 assessment by big data from a Japanese electronic health record. Heart Vessels 38(6):793\u2013802. https:\/\/doi.org\/10.1007\/s00380-023-02238-9","journal-title":"Heart Vessels"},{"issue":"10","key":"2680_CR19","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1093\/sleep\/29.10.1301","volume":"29","author":"AA Patwardhan","year":"2006","unstructured":"Patwardhan AA, Larson MG, Levy D, Benjamin EJ, Leip EP, Keyes MJ, Wang TJ, Gottlieb DJ, Vasan RS (2006) Obstructive sleep apnea and plasma natriuretic peptide levels in a community-based sample. Sleep 29(10):1301\u20131306. https:\/\/doi.org\/10.1093\/sleep\/29.10.1301","journal-title":"Sleep"},{"issue":"1","key":"2680_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1161\/CIRCOUTCOMES.109.854877","volume":"3","author":"PN Peterson","year":"2010","unstructured":"Peterson PN, Rumsfeld JS, Liang L, Albert NM, Hernandez AF, Peterson ED, Fonarow GC, Masoudi FA, American Heart Association Get With the Guidelines-Heart Failure P (2010) A validated risk score for in-hospital mortality in patients with heart failure from the American Heart Association get with the guidelines program. Circ Cardiovasc Qual Outcomes 3(1):25\u201332. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.109.854877","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"19","key":"2680_CR21","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1093\/eurheartj\/ehs337","volume":"34","author":"SJ Pocock","year":"2013","unstructured":"Pocock SJ, Ariti CA, McMurray JJ, Maggioni A, Kober L, Squire IB, Swedberg K, Dobson J, Poppe KK, Whalley GA, Doughty RN, Meta-Analysis Global Group in Chronic Heart Failure (2013) Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J 34(19):1404\u20131413. https:\/\/doi.org\/10.1093\/eurheartj\/ehs337","journal-title":"Eur Heart J"},{"issue":"8","key":"2680_CR22","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s00380-023-02252-x","volume":"38","author":"N Taniguchi","year":"2023","unstructured":"Taniguchi N, Miyasaka Y, Suwa Y, Harada S, Nakai E, Shiojima I (2023) H(2)ARDD score as a feasible predictor of heart failure events in patients with atrial fibrillation: a validation study. Heart Vessels 38(8):1035\u20131041. https:\/\/doi.org\/10.1007\/s00380-023-02252-x","journal-title":"Heart Vessels"},{"issue":"36","key":"2680_CR23","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A, Group ESCSD (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599\u20133726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"issue":"10","key":"2680_CR24","doi-asserted-by":"publisher","first-page":"100688","DOI":"10.1016\/j.jacadv.2023.100688","volume":"2","author":"S Jehn","year":"2023","unstructured":"Jehn S, Mahabadi AA, Pfohl C, Vogel L, Al-Rashid F, Luedike P, Totzeck M, Rassaf T, Dykun I (2023) BNP and NT-proBNP thresholds for the assessment of prognosis in patients without heart failure. JACC Adv 2(10):100688. https:\/\/doi.org\/10.1016\/j.jacadv.2023.100688","journal-title":"JACC Adv"},{"key":"2680_CR25","doi-asserted-by":"publisher","unstructured":"Kitai T, Kohsaka S, Kato T, Kato E, Sato K, Teramoto K, Yaku H, Akiyama E, Ando M, Izumi C, Ide T, Iwasaki YK, Ohno Y, Okumura T, Ozasa N, Kaji S, Kashimura T, Kitaoka H, Kinugasa Y, Kinugawa S, Toda K, Nagai T, Nakamura M, Hikoso S, Minamisawa M, Wakasa S, Anchi Y, Oishi S, Okada A, Obokata M, Kagiyama N, Kato NP, Kohno T, Sato T, Shiraishi Y, Tamaki Y, Tamura Y, Nagao K, Nagatomo Y, Nakamura N, Nochioka K, Nomura A, Nomura S, Horiuchi Y, Mizuno A, Murai R, Inomata T, Kuwahara K, Sakata Y, Tsutsui H, Kinugawa K, Japanese Circulation Society, The Japanese Heart Failure Society Joint Working Group (2025) JCS\/JHFS 2025 guideline on diagnosis and treatment of heart failure. J Card Fail 31(8):1164\u20131322. https:\/\/doi.org\/10.1016\/j.cardfail.2025.02.014","DOI":"10.1016\/j.cardfail.2025.02.014"},{"issue":"9","key":"2680_CR26","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/j.cardfail.2025.03.005","volume":"31","author":"M Minamisawa","year":"2025","unstructured":"Minamisawa M, Anzai T, Inomata T, Kinugawa K, Sakata Y, Sato N, Tsutsui H, Yamamoto K, Yoshimura M, Saito Y, Kuwahara K (2025) 2023 Update of the Japanese Heart Failure Society scientific statement on BNP and NT-proBNP levels in heart failure practice. J Card Fail 31(9):1453\u20131459. https:\/\/doi.org\/10.1016\/j.cardfail.2025.03.005","journal-title":"J Card Fail"}],"container-title":["Heart and Vessels"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-026-02680-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00380-026-02680-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-026-02680-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:06:26Z","timestamp":1792231586000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00380-026-02680-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,5]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["2680"],"URL":"https:\/\/doi.org\/10.1007\/s00380-026-02680-5","relation":{},"ISSN":["0910-8327","1615-2573"],"issn-type":[{"value":"0910-8327","type":"print"},{"value":"1615-2573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,5]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.H. received lecture fees from TriNetX, Roche, Eli Lilly, Boehringer, and AstraZeneca and research funding from Asahi Intec. L.D. has received consulting fees from Abbott, QuidelOrtho, and Roche Diagnostics and serves on the clinical endpoint education committee for Tosoh. K.T. received lecture fees from Abiomed, Boehringer Ingelheim, Otsuka Pharmaceutical, Toray, Eli Lilly, Novartis Pharma, Bayer, and Pfizer. Others have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}